Rapamycin and Rapalogs in Cancer Therapy

Abstract

mTOR signaling is frequently upregulated in cancer and supports tumor growth by promoting protein synthesis, metabolism and survival programs. Rapamycin and rapalogs, as they inhibit the mTOR pathway, remain important anticancer agents. This paper summarizes how rapamycin-centered cancer treatment strategies can inhibit mTORC1 outputs and explains why pathway inhibition does not always translate into significant tumor control. Mechanistically, rapamycin reduces mTORC1-dependent translation signals, but the clinical effect varies because tumors differ in pathway dependence and can engage compensatory circuits. Key determinants of heterogeneous response include feedback activation within the mTOR network, incomplete suppression of mTOR-complex functions, and autophagy. Evidence from tumor studies shows that rapalogs can achieve tumor suppression in most cases, yet these effects are often limited. Preclinical findings, on the other hand, support that cellular context can determine whether mTORC1 inhibition slows proliferation or is bypassed by alternative growth pathways. In conclusion, the paper argues that rapamycin is most useful when used with biomarker guidance and combinations that anticipate feedback and adaptive responses. These results motivate future work focused on improving patient selection and clarifying tumor-specific resistance mechanisms.